This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for Facebook, Verizon & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Verizon Communications (VZ) and Sanofi (SNY).
Glaxo (GSK)/Sanofi Delay Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an improved antigen formulation.
Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates
by Kinjel Shah
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.
Inflation to Pick Up in 2021: Bet on TIPS ETFs
by Sweta Killa
The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.
Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD
by Sweta Killa
While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.
Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study
by Zacks Equity Research
Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.
Glaxo's (GSK) Nucala Filing for Nasal Polyps Accepted by FDA
by Zacks Equity Research
The FDA accepts Glaxo's (GSK) regulatory filing for Nucala to treat patients with chronic rhinosinusitis with nasal polyps. The drug is already approved for three other indications.
Regeneron (REGN) Posts Upbeat Data on Myeloma Candidate at ASH
by Zacks Equity Research
Regeneron (REGN) releases encouraging data from early-stage study on REGN5458 at the ASH 2020.
Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion
by Zacks Equity Research
Regeneron (REGN) and Sanofi win EC nod for Dupixent for the indication of severe atopic dermatitis in children 6 to 11 years of age.
Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal
by Kinjel Shah
AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.
Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval
by Zacks Equity Research
The European Commission nods to Sanofi's (SNY) MenQuadfi, a meningococcal vaccine for individuals, aged 12 months and older.
Glaxo's (GSK) RSV Vaccine for Pregnant Women Enters Phase III
by Zacks Equity Research
Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.
Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.
Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag
by Zacks Equity Research
The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.
Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection
by Zacks Equity Research
The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.
Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates
by Zacks Equity Research
Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.
Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View
by Zacks Equity Research
Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance. Stock slides in after-hours trading.
BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.
Regeneron's (REGN) Q3 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on both earnings and sales in the third quarter of 2020 on strong performances by Eylea and Dupixent. Shares rise in pre-market trading.
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.
What's in the Cards for Regeneron's (REGN) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.
Sanofi's (SNY) Q3 Earnings & Sales Miss, 2020 View Raised
by Zacks Equity Research
Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?
by Zacks Equity Research
During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT